-
Australia's new Ghost Shark submarines grow some 'teeth'
-
China's third-quarter growth narrowly beats forecasts
-
'I call it a bribe': Pennsylvania residents spurn $10,000 data center checks
-
Asian stocks start week on back foot, tracking tech-led Wall St losses
-
In a former US steel city, ordinary people struggle to get by
-
China growth narrowly beats forecasts
-
'Liar,' 'clown': Lula and Bolsonaro spar in Brazil poll debate
-
Faith and fury: Texas Senate rivals offer contrasting visions
-
Record El Nino? Depends who's counting
-
Women await justice for police killings in Brazil
-
On the front line of ocean conservation off Portugal's Madeira
-
The painstaking task of cataloguing the world's species
-
Wembanyama targets title breakthrough as NBA season tips off
-
Nations seek reset at UN talks as nature goals off track
-
With LeBron on board it's title or bust for Philly fans
-
Rubio seeks to strengthen US foothold in Central Asia
-
One year after Louvre heist, where are the missing jewels?
-
LeBron joins 76ers to chase one more NBA title at age 41
-
Knicks face tall task in NBA championship repeat bid
-
Rays one win from World Series return after downing Guardians
-
Warriors' Curry 'fine' after limping out of practice - Kerr
-
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - October 19
-
Caledonia Mining Corporation Plc: Notification of Relevant Change To Significant Shareholder
-
Hemogenyx Pharmaceuticals PLC Announces Feasibility Study Agreement
-
Kings' Ben Simmons tears Achilles in training
-
Zelensky speaks to US envoys as Trump lashes out
-
Lula, Bolsonaro set for first debate showdown in bitter election race
-
'Surprise package' Lazio crush Juve to keep pace with Serie A leaders Inter
-
Mbappe hits two as Real Madrid rout Sevilla
-
China growth expected to miss official target in third quarter
-
Browns edge Ravens for division lead, Texans beat Jags
-
Lazio crush Juventus to move level with Serie A leaders Inter
-
Lyon go top of Ligue 1 as Monaco fall to first defeat of the season
-
Leeds draw feels like 'fresh start' for Man Utd's Carrick
-
Venezuela opposition alliance reaffirms Nobel laureate Machado as leader
-
Macron denounces 'unbridled' violence as France hit by new clashes
-
'Street Fighter' wins N. America box office, buzzy doc stuns in 2nd
-
Hurzeler lauds 'hard worker' Gomez after Brighton goal from halfway line
-
NFL: Paris game to go ahead despite protests in France
-
Toulouse hold off Exeter, Northampton save English Champions Cup blushes
-
Arteta hails Arsenal 'finishers' after Madueke fells Forest
-
Arsenal snatch late win to keep pressure on Man City as Man Utd held
-
Trump backs ally Netanyahu ahead of Israel's tight election
-
Arsenal strike late to keep pressure on Man City as Man Utd held
-
Madueke strikes late as below-par Arsenal sink Forest
-
Four soldiers dead, dozens injured in fire at Canada military base
-
Second day of street clashes in Milan
-
Ton-up Agha helps Pakistan down Sri Lanka in tri-series opener
-
Dupont's Toulouse hold off Exeter as English Champions Cup woes continue
MIB Agents' Community of Families Has Awarded $2.9M in Grants to Research Pediatric Bone Cancer
Leading Pediatric Osteosarcoma Nonprofit to Present $400,000 to 5 Scientists During Annual Conference to Find Kinder Treatments for Patients
BARNARD, VT / ACCESS Newswire / June 16, 2026 / MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, announced today that since its inception in 2016, it has awarded $2.9 million to scientists across the country through its OutSmarting Osteosarcoma grant program. The OutSmarting Osteosarcoma grants are supported by MIB Agents Family Funds, osteosarcoma patients and families who raise research dollars in honor of an OsteoWarrior, a patient currently battling osteosarcoma or an OsteoAngel, a loved one who has passed.
As part of MIB Agents' FACTOR Conference taking place June 25-27 in Columbus, Ohio, where clinicians, researchers, industry partners, survivors, patients and bereaved families gather to collaborate and discuss progress in osteosarcoma research, the nonprofit will award $400,000 in grants to 5 scientists dedicated to moving osteosarcoma cancer research forward. Osteosarcoma is an aggressive, malignant, primary bone cancer affecting an estimated 1,000 people in the U.S. each year and is the most common bone cancer affecting children and young adults.
"I'm so grateful for this amazing award!" said Seth Pollack, MD, the Steven T. Rosen, MD, Professor of Cancer Biology and Professor of Medicine in the division of Hematology and Oncology at Northwestern University Feinberg School of Medicine. "This research is at a stage where we are so close to testing this in the clinic and helping patients, but we still have some final hurdles; I believe this funding will get us there."
Dr. Pollack is one of three scientists selected to receive a $100,000 Hero Grant, the highest funding level awarded through the OutSmarting Osteosarcoma program. These awards recognize bold, innovative research projects poised to make a significant impact in the fight against osteosarcoma.
The OutSmarting Osteosarcoma grant represents a partnership between the scientific and patient community with patients and their families funding much-needed research. Patients and caregivers participate in the MIB Agents robust scientific review process alongside scientists, clinicians and researchers, offering a voice on how research will impact patient outcomes.
The OutSmarting Osteosarcoma 2026 grant recipients, receiving $100,000 Hero grants each for research will be awarded to:
Lindsay Talbot, MD | St. Jude Children's Research Hospital | Granted Because of all Family Funds
Seth Pollack, MD | Northwestern University | Granted Because of Patrick
Theodore S. Nowicki, MD, PhD | University of California, Los Angeles | Granted Because of Buddy
Two recipients will receive a $50,000 Hope Young Investigator grant:
Alice Browne, PhD | National Cancer Institute | Granted Because of Annaleigh
Andrew Wahba, MD | Baylor College of Medicine / Texas Children's | Granted Because of Charlotte
Among the families fueling this year's grants is Liz and Michael Newman, whose son Patrick fought courageously from his initial diagnosis in 2018, through his metastatic disease relapses that started in 2024. Patrick requested that all his money support research for the other kids with osteosarcoma, and his life savings of $10,331 were donated to establish a MIB Agents Family Fund in his memory to support research through MIB Agents. "We are so pleased to fund Dr. Pollack's novel approach for immunotherapy to fight osteosarcoma," said Liz and Michael Newman. "The current decades-old treatment protocol fails too many children like Patrick, who relapsed after 5 years. Patrick aspired to be a researcher himself and would be encouraged by these new developments."
To learn more about MIB Agents, the OutSmarting Osteosarcoma grant program or to make a donation toward pediatric osteosarcoma research, please click here.
About MIB Agents
Founded in 2012, MIB Agents is a leading pediatric osteosarcoma nonprofit dedicated to making it better for our community of patients, caregivers, doctors, and researchers through programs, education, and research.
MEDIA CONTACT
Alanna Anderson
[email protected]
281-770-9084
SOURCE: MIB Agents
View the original press release on ACCESS Newswire
A.Malone--AMWN